Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background There is a paucity of effective systemic therapy options for patients with advanced, chemotherapy-refractory colorectal cancer. We aimed to evaluate the efficacy and safety of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3, in patients with heavily pretreated metastatic colorectal cancer.Methods We conducted an international, randomised, double-blind, placebo-controlled, phase 3 study (FRESCO-2) at 124 hospitals and cancer centres across 14 countries. We included patients aged 18 years or older (≥20 years in Japan) with histologically or cytologically documented metastatic colorectal adenocarcinoma who had received all current standard approved cytotoxic and targeted therapies and progressed on or were intolerant to trifluridine-tipiracil or regorafenib, or both. Eligible patients were randomly assigned (2:1) to receive fruquintinib (5 mg capsule) or matched placebo orally once daily on days 1-21 in 28-day cycles, plus best supportive care. Stratification factors were previous trifluridine-tipiracil or regorafenib, or both, RAS mutation status, and duration of metastatic disease. Patients, investigators, study site personnel, and sponsors, except for selected sponsor pharmacovigilance personnel, were masked to study group assignments. The primary endpoint was overall survival, defined as the time from randomisation to death from any cause. A non-binding futility analysis was done when approximately one-third of the expected overall survival events had occurred. Final analysis occurred after 480 overall survival events. This study is registered with ClinicalTrials.gov, NCT04322539, and EudraCT, 2020-000158-88, and is ongoing but not recruiting.Findings Between Aug 12, 2020, and Dec 2, 2021, 934 patients were assessed for eligibility and 691 were enrolled and randomly assigned to receive fruquintinib (n=461) or placebo (n=230). Patients had received a median of 4 lines (IQR 3-6) of previous systemic therapy for metastatic disease, and 502 (73%) of 691 patients had received more than 3 lines. Median overall survival was 7·4 months (95% CI 6·7-8·2) in the fruquintinib group versus 4·8 months (4·0-5·8) in the placebo group (hazard ratio 0·66, 95% CI 0·55-0·80; p<0·0001). Grade 3 or worse adverse events occurred in 286 (63%) of 456 patients who received fruquintinib and 116 (50%) of 230 who received placebo; the most common grade 3 or worse adverse events in the fruquintinib group included hypertension (n=62 [14%]), asthenia (n=35 [8%]), and hand-foot syndrome (n=29 [6%]). There was one treatment-related death in each group (intestinal perforation in the fruquintinib group and cardiac arrest in the placebo group).Interpretation Fruquintinib treatment resulted in a significant and clinically meaningful benefit in overall survival compared with placebo in patients with refractory metastatic colorectal cancer. These data support the use of fruquintinib as a global treatment option for patients with refractory metastatic colorectal cancer. Ongoing analysis of the quality of life data will further establish the clinical benefit of fruquintinib in this patient population.Funding HUTCHMED.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Median overall survival was 7.4 months in the fruquitinib group versus 4.8 months in the placebo group (p < 0.001).”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [62]
In the citing paper
“The low efficacy of current late-line standard of care trifluridine/tipiracil plus bevacizumab (SUNLIGHT trial; median PFS 5.6 months; ORR 6%), fruquintinib (median PFS 3.7 months; ORR 2%), or regorafenib (median PFS 1.9 months; ORR 1%) underscores the high unmet need in heavily pretreated patients (23–25).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [24]
In the citing paper
“In FRESCO-1, fruquintinib showed significant benefits in both overall survival (OS) and progression-free survival (PFS) compared to placebo. Subgroup analyses reported an OS hazard ratio (HR) of 0.56 in KRAS wild-type (WT) patients and 0.75 in KRAS-mutant patients.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [49]
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Self-citationCervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Self-citationComprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Self-citationLi, J., Qin, S., Xu, R.-H., Shen, L., Xu, J., Bai, Y., Yang, L., Deng, Y., Chen, Z.-D., Zhong, H., et al. (2018) · JAMA · doi:10.1001/jama.2018.7855 · Cited by 425
Sun, Q., Zhou, J., Zhang, Z., Guo, M., Liang, J., Zhou, F., Long, J., Zhang, W., Yin, F., Cai, H., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.964087 · Cited by 159
Self-citationVEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects
Duda, D. G., Batchelor, T. T., Willett, C. G., & Jain, R. K. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.04.001 · Cited by 156
Cited by
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Adam, M., Chang, G., Chen, Y.-J., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D., Garrido-Laguna, I., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0029 · Cited by 371
Eng, C., Yoshino, T., Ruíz-García, E., Mostafa, N., Cann, C. G., O'Brian, B., Benny, A., Perez, R. O., & Cremolini, C. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00360-x · Cited by 449
Self-citationSotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308795 · Cited by 398
Self-citationMulti-stage mechanisms of tumor metastasis and therapeutic strategies
Liu, Z., Chen, J., Ren, Y., Liu, S., Ba, Y., Zuo, A., Luo, P., Cheng, Q., Xu, H., & Han, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01955-5 · Cited by 184
“278,279 Additionally, to address unresectable diffuse peritoneal metastases and ascites formation in advanced CRC patients, the OxP/R848@PLEL hydrogel delivery system has been developed to effectively eradicate metastases and ascites, thereby prolonging patient survival.”
BackgroundColorectal cancer: Recent advances in management and treatment
Fadlallah, H., El Masri, J., Fakhereddine, H., Youssef, J., Chemaly, C., Doughan, S., & Abou-Kheir, W. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i9.1136 · Cited by 169
Metadata
- Authors
- Dasari, A., Lonardi, S., Garcia-Carbonero, R., Elez, E., Yoshino, T., Sobrero, A., Yao, J., García-Alfonso, P., Kocsis, J., Cubillo Gracian, A., Sartore-Bianchi, A., Satoh, T., Randrian, V., Tomasek, J., Chong, G., Paulson, A. S., Masuishi, T., Jones, J., Csőszi, T., Cremolini, C., Ghiringhelli, F., Shergill, A., Hochster, H. S., Krauss, J., Bassam, A., Ducreux, M., Elme, A., Faugeras, L., Kasper, S., Van Cutsem, E., Arnold, D., Nanda, S., Yang, Z., Schelman, W. R., Kania, M., Tabernero, J., & Eng, C.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Istituto Oncologico Veneto (IT)
- National Cancer Center Hospital East (JP)
- Ospedale Policlinico San Martino (IT)
- Bács-Kiskun Megyei Kórház (HU)
- Osaka University Hospital (JP)
- Université de Poitiers (FR)
- Austin Hospital (AU)
- Aichi Cancer Center (JP)
- Mayo Clinic in Florida (US)
- University of Pisa (IT)
- University of Chicago (US)
- University of Michigan (US)
- Békés Megyei Központi Kórház (HU)
- Inserm (FR)
- North Estonia Medical Centre (EE)
- CHU Dinant Godinne UCL Namur (BE)
- Essen University Hospital (DE)
- Asklepios Klinik Altona (DE)
- HUTCHMED (China) Limited (China) (HK)
- Vall d'Hebron Institute of Oncology (ES)
- Vanderbilt University (US)
- Corresponding author
- Dasari, Arvind
- ORCID
- Dasari, Arvind
- Lonardi, Sara
- Yoshino, Takayuki
- Sobrero, Alberto
- Yao, James
- Kocsis, Judit
- Satoh, Taroh
- Randrian, Violaine
- Paulson, Andrew Scott
- Masuishi, Toshiki
- Jones, Jeremy
- Csőszi, Tibor
- Cremolini, Chiara
- Shergill, Ardaman
- Krauss, John
- Ducreux, Michel
- Elme, Anneli
- Kasper, Stefan
- Arnold, Dirk
- Nanda, Shivani
- Tabernero, Josep
- Eng, Cathy
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2023-07
- Volume
- 402
- Issue
- 10395
- Pages
- 41-53
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4380887702
- Cited by
- 368
- References
- 17
- Citations by year
- 2026: 115 · 2025: 133 · 2024: 106 · 2023: 14
- FWCI
- 46.11
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, cc-by-nc-nd)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Funders
- Japan Society for the Promotion of Science (22K19559, 23K24405)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- fruquintinib, metastatic colorectal cancer, VEGFR inhibitors, refractory colorectal cancer, overall survival, trifluridine/tipiracil, regorafenib, RAS mutations, best supportive care, oral targeted therapy, safety and tolerability, RAS mutation status
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Benzofurans, Colonic Neoplasms, Double-Blind Method, Humans, Phenylurea Compounds, Pyridines, Quality of Life, Quinazolines, Rectal Neoplasms, Trifluridine, Colorectal Neoplasms, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. https://app.cochat.ai/papers/10.1016/s0140-6736(23)00772-9
- The paper
- Dasari, A., Lonardi, S., Garcia-Carbonero, R., Elez, E., Yoshino, T., Sobrero, A., Yao, J., García-Alfonso, P., Kocsis, J., Cubillo Gracian, A., Sartore-Bianchi, A., Satoh, T., Randrian, V., Tomasek, J., Chong, G., Paulson, A. S., Masuishi, T., Jones, J., Csőszi, T., . . . Eng, C. (2023). Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. The Lancet. https://doi.org/10.1016/s0140-6736(23)00772-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.